KNSA P&L Curve
Kiniksa Pharmaceuticals International, plc (KNSA) operates in the Healthcare sector, specifically the Medical - Pharmaceuticals industry, with a market capitalization near $4.45B, listed on NASDAQ, employing roughly 366 people, carrying a beta of 0.12 to the broader market. Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. Led by Sanj K. Patel, public since 2018-05-24.
A profit/loss curve charts the theoretical gain or loss of an options position across a range of underlying prices. It helps traders visualize risk, identify breakeven points, and compare strategies before committing capital.
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Market Cap
- $4.45B
- Employees
- 366
- IPO Date
- 2018-05-24
- CEO
- Sanj K. Patel
- Beta
- 0.12
At the current $63.84 spot price with 44.1% ATM implied volatility and 17 days to the front expiration, an at-the-money long straddle carries an approximate combined premium near $4.86, producing breakevens at roughly $58.98 and $68.70. Market-implied 1-standard-deviation range extends from $55.77 to $71.91, which sets the relevant P&L evaluation window for most near-term strategies. Payoff diagrams should be rebuilt from the live options chain; the preceding values are illustrative and assume a single at-the-money straddle for reference.
Frequently asked KNSA pl curve questions
- What does a KNSA ATM straddle cost today?
- Using current KNSA pricing (44.1% ATM IV, 17-day front expiration, $63.84 spot), an at-the-money long straddle (long call + long put at the same strike) carries an approximate combined premium near $4.86 per spread. Breakevens land at roughly $68.70 on the upside and $58.98 on the downside. The estimate uses the Brenner-Subrahmanyam approximation for at-the-money options under Black-Scholes.
- How do I read an options P&L curve?
- An options P&L curve plots theoretical position value at expiration (or at any chosen evaluation date) against the underlying price. The X-axis is the underlying price scenario, the Y-axis is position dollar P&L. The shape of the curve tells you the strategy's directional sensitivity, breakeven points, maximum profit and loss levels, and where time decay or volatility shifts will be most impactful. Multi-leg structures combine the curves of the individual legs to produce composite payoff diagrams.
- What's the difference between a P&L curve and a payoff diagram?
- Strictly: a payoff diagram shows option value at expiration (no time premium left), while a P&L curve typically shows position value at any evaluation date (with remaining time premium). The expiration payoff diagram has kinks at the strikes; the early P&L curve is smooth. For directional-vega trades, the early P&L curve also responds to IV shifts that the expiration payoff diagram does not capture - which is why options traders often look at both views.
- Why are illustrative KNSA P&L numbers approximate?
- The numbers above use Black-Scholes assumptions (lognormal returns, constant volatility, no early exercise, no dividends). Real-world option prices reflect skew, term structure, jump risk, and (for US-style options) early exercise premium. Use the live options chain for actual quoted bid/ask prices when sizing trades; the values here illustrate magnitude only.